

Almirall opens a new subsidiary for the Czech Republic and Slovakia

- The company is appointing David Festa as General Manager of the Czech Republic and Slovakia affiliate
- The new affiliate responds to Almirall's expansion strategy to support the company's gradual growth and to offer its treatments to a wider number of people living with dermatological diseases
- Almirall will start commercializing Ilumetri®▼ (tildrakizumab) in these two countries for the treatment of adult patients with severe chronic plaque psoriasis, following the recent approval of the reimbursed price

Barcelona (Spain), November 08, 2022.- Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, **announced the opening of a new affiliate for the Czech Republic and Slovakia** to strengthen its presence in these markets and its leadership in Europe in Medical Dermatology. The subsidiary will be managed from Prague by the recently appointed Czech Republic & Slovakia General Manager, David Festa.

The strategy set for Almirall in the Czech and Slovak markets, where until now the company was commercializing through distributors, is to work towards the launch of new products in these countries to further develop its established portfolio in Medical Dermatology. The company recently received the approval of the reimbursed price for Ilumetri® (tildrakizumab), an anti-IL-23 biologic for moderate-to-severe plaque psoriasis, in these two countries for the treatment of adult patients with severe chronic plaque psoriasis and has initiated its commercialization this month. The product has been continuously growing in EU countries such as Germany, where the anti-IL23 class holds a leading position of new patient market. The market for biologics to treat psoriasis in the Czech Republic and Slovakia amounts to 55 million euros and the growth of the IL-23 class is 47% in 2021 compared to 2020.

*"At Almirall, we are on the right track to become the leading medical dermatology company in Europe, which implies expanding our presence in Eastern Europe. Following the launch of our biologic for psoriasis in Poland early this year, we continue consolidating our portfolio in the Czech and Slovak markets that offer great business opportunities", stated **Paolo Cionini**, Almirall's Chief Commercial Officer of EU & International. "We are always on the lookout for new expansion options to complete our presence in this geography", he added.*

With the addition of these new subsidiary, Almirall now has 14 global affiliates strategically located in Europe and the United States and is present in more than 70 countries. In this way, the company continues its global approach to meet the unmet needs of patients with dermatological diseases around the world.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total

revenues in 2021 were 836.5 million euros.

For more information, please visit www.almirall.com

Media contact Almirall:

Tinkle

Laura Blázquez

lblazquez@tinkle.es

Phone: (+34) 600 430 581

Corporate Communications contact:

Almirall

Mar Ramírez

mar.ramirez@almirall.com

Phone: (+34) 659 61 41 73

Investors' Relations contact

Almirall

Pablo Divasson del Fraile

pablo.divasson@almirall.com

Phone: (+34) 93 291 3087

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.